Concurrent Session 10: Therapeutic Challenges: Pharmacological

Date/Time: Saturday, April 9, 2022 - 2:00 PM to 3:30 PM
Log in to Add to My Schedule

Description:

COVID-19: Impact on OA Care

Karin Magnusson, PT, PhD - Lund University

We will learn about what it means to OA patients to contract COVID-19 as well as how the COVID-19 pandemic with its disease control measures have affected the health care services for OA patients. 

We will learn about what it means to OA patients to contract COVID-19 as well as how the COVID-19 pandemic with its disease control measures have affected the health care services for OA patients. This includes knowledge of the risk for contracting severe COVID-19 as well as the consequences of having mild and severe COVID-19 in the short and the long term. It also includes knowledge of how different disease control measures that were implemented to control the virus, affect the care for OA patients, both the primary care services and the specialist care services. The session will touch upon topics like long-covid, effects of lockdown restrictions and how they relate to OA. It will also touch upon the interaction between commonly used OA interventions and commonly used interventions for COVID-19.

 

Abstract(s):

  • 79
    OPIOID USE PRIOR TO TOTAL KNEE REPLACEMENT: COMPARATIVE ANALYSIS OF TRENDS IN ENGLAND AND SWEDEN
    Clara Hellberg, PhD, Lund University

    80
    EFFECT OF TRANSDERMAL MICRONEEDLE PATCH WITH NSAID IN OSTEOARTHRITIC KNEE
    Thanainit Chotanaphuti presenting in place of Mongkon Pisuttanawat, MD, Phramongkutklaol College of medicine

    V-81
    CONTROLLED RELEASE OF CD200 INHIBITS INFLAMMATORY MACROPHAGES AND CHONDROCYTE CATABOLISM
    Tiffany Conklin presenting in place of Shreedevi Kumar, PhD, University of Florida

    82
    A CYCLIC-INVERSO AHSG/FETUINA-BASED PEPTIDE AS POTENT INHIBITOR OF CALCIFICATION FOR OSTEOARTHRITIS TREATMENT
    Guus G. van den Akker, PhD, Maastricht University

    83
    LNA043 A NOVEL CANDIDATE FOR OSTEOARTHRITIS TREATMENT INDUCES CARTILAGE REGENERATION AND REVERSES THE OSTEOARTHRITIS TRANSCRIPTOME
    Nicole Gerwin, Novartis Institutes for BioMedical Research

    V-84
    TALAROZOLE, A RETINOIC ACID METABOLISM BLOCKING AGENT, SUPPRESSES MECHANOFLAMMATION AND ATTENUATES THE DEVELOPMENT OF POST-TRAUMATIC OA
    Linyi Zhu, Kennedy Institute of Rheumatology, University of Oxford

Speaker(s):